Life sciences briefing: Thursday, Sept. 27, 2007
Featured companies: AstraZeneca, Atlantis Components, Cara Therapeutics, CardioMems, Corium International, New Ortho Polymers, Osprey Pharmaceuticals, Othera Pharmaceuticals, StrataGent Life Sciences
Corium acquires Stratagent, raises $25.1M for “transdermal” drugs — Corium International, a Menlo Park, Calif., biotech focused on drugs that can be delivered through the skin, said it will acquire StrataGent Life Sciences of San Jose, Calif., for an undisclosed sum. At the same time, Corium raised $25.1 million in a third funding round, and said it… Continue Reading
SpectraGenics draws at least $20M for laser hair removal
SpectraGenics, a Pleasanton, Calif., developer of laser hair-removal devices for home use, raised at least $20 million in a fourth round of funding, VentureWire reports (subscription required). The round was led by De Novo Ventures and Technology Partners; other investors included Aphelion Capital, Incubic Venture Capital and SDL Ventures.
SpectraGenics, which still seems to be fairly stealthy, sells a version of its hair-removal device in Japan under the name i-epi. If you read Japanese, or just… Continue Reading
StrataGent closes $16M round for needle-free injections
StrataGent Life Sciences, a San Jose developer of needle-free “microjet” injection systems, said it closed a $16 million second round of financing. The company has so far received $6.65 million of that round; the remainder should become available next year if and when StrataGent meets certain milestones.
The round was led by Essex Woodlands Health Ventures. Other investors include Quantum Technology Partners and Aphelion Capital.
StrataGent’s own description of what it’s up to in its funding release… Continue Reading